IP Library Granted Patent US 9,481,646
Granted Patent B2
US 9,481,646 · App. 12/596,252 · Granted Nov 1, 2016

Low calcemic, highly antiproliferative, analogs of calcitriol

Inventors: Gary H. Posner (Baltimore, MD); Kimberly S. Petersen (College Park, MD); Lindsey C. Hess (Baltimore, MD); Douglas T. Genna (Timonium, MD); Scott Borella (Charlotte, NC)
Assignee: The Johns Hopkins University
C07C401/00C07D307/42C07C2101/14C07C2101/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,481,646
App. No.
12/596,252
Granted
Nov 1, 2016
Kind
B2
Abstract

The disclosure provides compounds, compositions and methods using these compounds and compositions to stimulate the differentiation of cells and inhibit excessive cell proliferation of certain cells, including cancer cells and skin cells, which may be useful in the treatment of diseases characterized by abnormal cell proliferation and/or cell differentiation such as leukemia, myelofibrosis and psoriasis without the well known effect on calcium metabolism, which gives rise to hypercalcemia.

Claims (15)

1. A compound having formula I:

or a pharmaceutically acceptable salt thereof, wherein:

m is an integer from 0 to 1;

R 1 is selected from the group consisting of

 and

each n is independently an integer from 0 to 2.

2. The compound of claim 1 , wherein the compound of formula I has formula IV:

or a pharmaceutically acceptable salt thereof.

3. A method of treating a disorder characterized by abnormal cell-proliferation and/or cell-differentiation, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I of claim 1 , wherein the disorder is selected from the group consisting of leukemia, myelofibrosis and psoriasis.

4. A method of treating secondary hyperparathyroidism, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I of claim 1 .

5. A method of preparing the compound of formula I of claim 1 , comprising:

a) reacting the compound of formula XI with base to form the corresponding anion;

b) coupling the anion with the compound of formula XII, wherein PG is a protecting group; and

c) removing the protecting groups to provide the compound of formula I.

6. The method of claim 5 , wherein the base is an alkali metal hydride or organolithium compound; and the protecting group is a silyl protecting group.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 13, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044428/0540 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2010
From: POSNER, GARY H.; PETERSEN, KIMBERLY S.; HESS, LINDSEY C.; GENNA, DOUGLAS T.; BORELLA, SCOTT
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 023849/0510 →
Continuity (2)
Provisional Application 60923998 · Apr 18, 2007
Related Publication 20100137262A1 · Jun 3, 2010